Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 5258727, 14 pages
http://dx.doi.org/10.1155/2016/5258727
Review Article

Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland

Received 18 February 2016; Accepted 8 May 2016

Academic Editor: Oreste Gualillo

Copyright © 2016 Gillian M. Lavelle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Yoshimura, H. Nakamura, B. C. Trapnell et al., “Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin,” Nucleic Acids Research, vol. 19, no. 19, pp. 5417–5423, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Riordan, J. M. Rommens, B.-S. Kerem et al., “Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA,” Science, vol. 245, no. 4922, pp. 1066–1073, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. The Cystic Fibrosis Registry of Ireland, 2012 Annual Report, The Cystic Fibrosis Registry of Ireland, Dublin, Ireland, 2012.
  4. Cystic Fibrosis Foundation, Patient Registry—Annual Data Report 2012, Cystic Fibrosis Foundation, Bethesda, Md, USA, 2012.
  5. L. Zhang, B. Button, S. E. Gabriel et al., “CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium,” PLoS Biology, vol. 7, no. 7, Article ID e1000155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. Armstrong, K. Grimwood, J. B. Carlin et al., “Lower airway inflammation in infants and young children with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 4, pp. 1197–1204, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. M. W. Konstan, K. A. Hilliard, T. M. Norvell, and M. Berger, “Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 2, pp. 448–454, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Boucher, “New concepts of the pathogenesis of cystic fibrosis lung disease,” European Respiratory Journal, vol. 23, no. 1, pp. 146–158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Gernez, C. E. Dunn, C. Everson et al., “Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens,” Journal of Cystic Fibrosis, vol. 11, no. 6, pp. 502–510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. H. P. J. van der Doef, F. T. M. Kokke, C. K. van der Ent, and R. H. J. Houwen, “Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation,” Current Gastroenterology Reports, vol. 13, no. 3, pp. 265–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Kelly and J. Buxbaum, “Gastrointestinal manifestations of cystic fibrosis,” Digestive Diseases and Sciences, vol. 60, no. 7, pp. 1903–1913, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. The Cystic Fibrosis Registry of Ireland, 2013 Annual Report, The Cystic Fibrosis Registry of Ireland, Dublin, Ireland, 2013.
  13. S. M. Moskowitz, J. F. Chmiel, D. L. Sternen et al., “Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders,” Genetics in Medicine, vol. 10, no. 12, pp. 851–868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Y. D. Wong, “CFTR gene and male fertility,” Molecular Human Reproduction, vol. 4, no. 2, pp. 107–110, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. T. Fisher, Y. Zhang, and J. F. Engelhardt, “Comparative biology of cystic fibrosis animal models,” Methods in Molecular Biology, vol. 742, pp. 311–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. S. Rogers, Y. Hao, T. Rokhlina et al., “Production of CFTR-null and CFTR-ΔF508 heterozygous pigs by adeno-associated virus–mediated gene targeting and somatic cell nuclear transfer,” The Journal of Clinical Investigation, vol. 118, no. 4, pp. 1571–1577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Stoltz, D. K. Meyerholz, A. A. Pezzulo et al., “Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth,” Science Translational Medicine, vol. 2, no. 29, Article ID 29ra31, 18 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Sun, H. Sui, J. T. Fisher et al., “Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3149–3160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Sun, A. K. Olivier, B. Liang et al., “Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 3, pp. 502–512, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. N. W. Keiser, S. E. Birket, I. A. Evans et al., “Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs,” American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 6, pp. 683–694, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Smith, P. H. Karp, and M. J. Welsh, “Defective fluid transport by cystic fibrosis airway epithelia,” The Journal of Clinical Investigation, vol. 93, no. 3, pp. 1307–1311, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. J. B. Lyczak, C. L. Cannon, and G. B. Pier, “Lung infections associated with cystic fibrosis,” Clinical Microbiology Reviews, vol. 15, no. 2, pp. 194–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Mall, B. R. Grubb, J. R. Harkema, W. K. O'Neal, and R. C. Boucher, “Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice,” Nature Medicine, vol. 10, no. 5, pp. 487–493, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Haerteis, B. Krueger, C. Korbmacher, and R. Rauh, “The δ-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation,” The Journal of Biological Chemistry, vol. 284, no. 42, pp. 29024–29040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Waldmann, G. Champigny, F. Bassilana, N. Voilley, and M. Lazdunski, “Molecular cloning and functional expression of a novel amiloride-sensitive Na+ channel,” Journal of Biological Chemistry, vol. 270, no. 46, pp. 27411–27414, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Althaus, “ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art,” Current Molecular Pharmacology, vol. 6, no. 1, pp. 3–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Pohl, E. Hayes, J. Keenan et al., “A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy,” Blood, vol. 124, no. 7, pp. 999–1009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. B. Butterworth, “Regulation of the epithelial sodium channel (ENaC) by membrane trafficking,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1802, no. 12, pp. 1166–1177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Lu, Q. Leng, M. E. Egan et al., “CFTR is required for PKA-regulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 797–807, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. M. Rommens, “Cystic Fibrosis Mutation Database,” http://www.genet.sickkids.on.ca/Home.html.
  31. E. Hayes, K. Pohl, N. G. McElvaney, and E. P. Reeves, “The cystic fibrosis neutrophil: a specialized yet potentially defective cell,” Archivum Immunologiae et Therapiae Experimentalis, vol. 59, no. 2, pp. 97–112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. L. Lukacs, X.-B. Chang, C. Bear et al., “The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane: determination of functional half-lives on transfected cells,” Journal of Biological Chemistry, vol. 268, no. 29, pp. 21592–21598, 1993. View at Google Scholar · View at Scopus
  33. J. Bott, S. Blumenthal, M. Buxton et al., “Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient,” Thorax, vol. 64, no. 1, pp. i1–i52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Robinson, A. L. Hemming, J. A. Regnis et al., “Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis,” Thorax, vol. 52, no. 10, pp. 900–903, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Wark and V. M. McDonald, “Nebulised hypertonic saline for cystic fibrosis,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD001506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. E. P. Reeves, M. Williamson, S. J. O'Neill, P. Greally, and N. G. McElvaney, “Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 11, pp. 1517–1523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Christopher, D. Chase, K. Stein, and R. Milne, “rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease,” Journal of Clinical Pharmacy and Therapeutics, vol. 24, no. 6, pp. 415–426, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Hofer, C. Benden, I. Inci et al., “True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience,” The Journal of Heart and Lung Transplantation, vol. 28, no. 4, pp. 334–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. F. J. Accurso, S. M. Rowe, J. P. Clancy et al., “Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation,” The New England Journal of Medicine, vol. 363, no. 21, pp. 1991–2003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. B. W. Ramsey, J. Davies, N. G. McElvaney et al., “A CFTR potentiator in patients with cystic fibrosis and the G551D mutation,” The New England Journal of Medicine, vol. 365, no. 18, pp. 1663–1672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S. M. Rowe, S. L. Heltshe, T. Gonska et al., “Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 175–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. L. R. Reznikov, M. H. Abou Alaiwa, C. L. Dohrn et al., “Antibacterial properties of the CFTR potentiator ivacaftor,” Journal of Cystic Fibrosis, vol. 13, no. 5, pp. 515–519, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. P. E. Bratcher, S. M. Rowe, G. Reeves et al., “Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor,” Journal of Cystic Fibrosis, vol. 15, no. 1, pp. 67–73, 2016. View at Publisher · View at Google Scholar
  44. P. A. Flume, T. G. Liou, D. S. Borowitz et al., “Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation,” Chest, vol. 142, no. 3, pp. 718–724, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. Vertex Pharmaceuticals Incorporated Report, “Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation,” 2014.
  46. C. E. Wainwright, J. S. Elborn, B. W. Ramsey et al., “Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR,” The New England Journal of Medicine, vol. 373, no. 3, pp. 220–231, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. FDA, “FDA approves new treatment for cystic fibrosis,” http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm.
  48. B.-S. Kerem, J. M. Rommens, J. A. Buchanan et al., “Identification of the cystic fibrosis gene: genetic analysis,” Science, vol. 245, no. 4922, pp. 1073–1080, 1989. View at Publisher · View at Google Scholar · View at Scopus
  49. J. N. Snouwaert, K. K. Brigman, A. M. Latour et al., “An animal model for cystic fibrosis made by gene targeting,” Science, vol. 257, no. 5073, pp. 1083–1088, 1992. View at Publisher · View at Google Scholar · View at Scopus
  50. D. J. Davidson and J. R. Dorin, “The CF mouse: an important tool for studying cystic fibrosis,” Expert Reviews in Molecular Medicine, vol. 3, pp. 1–27, 2004. View at Google Scholar
  51. R. Ratcliff, M. J. Evans, A. W. Cuthbert et al., “Production of a severe cystic fibrosis mutation in mice by gene targeting,” Nature Genetics, vol. 4, no. 1, pp. 35–41, 1993. View at Publisher · View at Google Scholar · View at Scopus
  52. W. K. O'Neal, P. Hasty, P. B. McCray Jr. et al., “A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus,” Human Molecular Genetics, vol. 2, no. 10, pp. 1561–1569, 1993. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Hasty, W. K. O'Neal, K.-Q. Liu et al., “Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene,” Somatic Cell and Molecular Genetics, vol. 21, no. 3, pp. 177–187, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Rozmahel, M. Wilschanski, A. Matin et al., “Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor,” Nature Genetics, vol. 12, no. 3, pp. 280–287, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. J. H. van Doorninck, P. J. French, E. Verbeek et al., “A mouse model for the cystic fibrosis ΔF508 mutation,” The EMBO Journal, vol. 14, no. 18, pp. 4403–4411, 1995. View at Google Scholar · View at Scopus
  56. B. G. Zeiher, E. Eichwald, J. Zabner et al., “A mouse model for the delta F508 allele of cystic fibrosis,” The Journal of Clinical Investigation, vol. 96, no. 4, pp. 2051–2064, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. W. H. Colledge, B. S. Abella, K. W. Southern et al., “Generation and characterization of a ΔF508 cystic fibrosis mouse model,” Nature Genetics, vol. 10, no. 4, pp. 445–452, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Dickinson, S. N. Smith, S. Webb et al., “The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics,” Human Molecular Genetics, vol. 11, no. 3, pp. 243–251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. S. J. Delaney, E. W. F. W. Alton, S. N. Smith et al., “Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations,” The EMBO Journal, vol. 15, no. 5, pp. 955–963, 1996. View at Google Scholar · View at Scopus
  60. J. R. Dorin, P. Dickinson, E. W. F. W. Alton et al., “Cystic fibrosis in the mouse by targeted insertional mutagenesis,” Nature, vol. 359, no. 6392, pp. 211–215, 1992. View at Publisher · View at Google Scholar · View at Scopus
  61. J. R. Dorin, P. Dickinson, E. Emslie et al., “Successful targeting of the mouse cystic fibrosis transmembrane conductance regulator gene in embryonal stem cells,” Transgenic Research, vol. 1, no. 2, pp. 101–105, 1992. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch, “Cystic fibrosis mouse models,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 1, pp. 1–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. D. J. Davidson and M. Rolfe, “Mouse models of cystic fibrosis,” Trends in Genetics, vol. 17, no. 10, pp. S29–S37, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Wilke, R. M. Buijs-Offerman, J. Aarbiou et al., “Mouse models of cystic fibrosis: phenotypic analysis and research applications,” Journal of Cystic Fibrosis, vol. 10, no. 2, pp. S152–S171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Johannesson, S. Hirtz, J. Schatterny, C. Schultz, and M. A. Mall, “CFTR regulates early pathogenesis of chronic obstructive lung disease in βenac-overexpressing mice,” PLoS ONE, vol. 7, no. 8, article e44059, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Ma and Y. Yang, “Epithelial sodium channel (ENaC),” Journal of American Science, vol. 5, no. 6, pp. 62–69, 2009. View at Google Scholar
  67. M. E. Egan, “How useful are cystic fibrosis mouse models?” Drug Discovery Today: Disease Models, vol. 6, no. 2, pp. 35–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. L. L. Clarke, B. R. Grubb, J. R. Yankaskas, C. U. Cotton, A. McKenzie, and R. C. Boucher, “Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(−/−) mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 2, pp. 479–483, 1994. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Gosselin, M. M. Stevenson, E. A. Cowley et al., “Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 4, part 1, pp. 1253–1262, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. U. Sajjan, G. Thanassoulis, V. Cherapanov et al., “Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr−/− mice,” Infection and Immunity, vol. 69, no. 8, pp. 5138–5150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Van Heeckeren, R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis, and T. Ferkol, “Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa,” The Journal of Clinical Investigation, vol. 100, no. 11, pp. 2810–2815, 1997. View at Publisher · View at Google Scholar · View at Scopus
  72. V. S. Shah, D. K. Meyerholz, X. X. Tang et al., “Airway acidification initiates host defense abnormalities in cystic fibrosis mice,” Science, vol. 351, no. 6272, pp. 503–507, 2016. View at Publisher · View at Google Scholar
  73. S. Gehrig, J. Duerr, M. Weitnauer et al., “Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosislike lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1082–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Borowitz and D. Gelfond, “Intestinal complications of cystic fibrosis,” Current Opinion in Pulmonary Medicine, vol. 19, no. 6, pp. 676–680, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. N. W. Keiser and J. F. Engelhardt, “New animal models of cystic fibrosis: what are they teaching us?” Current Opinion in Pulmonary Medicine, vol. 17, no. 6, pp. 478–483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. S. M. Rowe, S. Miller, and E. J. Sorscher, “Cystic fibrosis,” The New England Journal of Medicine, vol. 352, no. 19, pp. 1992–2001, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. J. R. Dorin, B. J. Stevenson, S. Fleming, E. W. F. W. Alton, P. Dickinson, and D. J. Porteous, “Long-term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type Cftr gene expression,” Mammalian Genome, vol. 5, no. 8, pp. 465–472, 1994. View at Publisher · View at Google Scholar · View at Scopus
  78. P. G. Noone and M. R. Knowles, “‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations,” Respiratory Research, vol. 2, no. 6, pp. 328–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Y. H. Leung, P. Y. D. Wong, J. R. Yankaskas, and R. C. Boucher, “cAMP- but not Ca(2+)-regulated Cl- conductance is lacking in cystic fibrosis mice epididymides and seminal vesicles,” American Journal of Physiology—Cell Physiology, vol. 271, no. 1, part 1, pp. C188–C193, 1996. View at Google Scholar · View at Scopus
  80. C. A. Hodges, M. R. Palmert, and M. L. Drumm, “Infertility in females with cystic fibrosis is multifactorial: evidence from mouse models,” Endocrinology, vol. 149, no. 6, pp. 2790–2797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Du, X. Liu, E. M. Welch, S. Hirawat, S. W. Peltz, and D. M. Bedwell, “PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2064–2069, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. X. Xue, V. Mutyam, L. Tang et al., “Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 4, pp. 805–816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Robert, G. W. Carlile, J. Liao et al., “Correction of the ΔPhe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine,” Molecular Pharmacology, vol. 77, no. 6, pp. 922–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Noël, M. Wilke, A. G. M. Bot, H. R. De Jonge, and F. Becq, “Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 1016–1023, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Vidović, M. S. Carlon, M. F. da Cunha et al., “rAAV-CFTRΔR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 3, pp. 288–298, 2016. View at Publisher · View at Google Scholar
  86. M. A. Mall and L. J. V. Galietta, “Targeting ion channels in cystic fibrosis,” Journal of Cystic Fibrosis, vol. 14, no. 5, pp. 561–570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. L. S. Ostedgaard, D. K. Meyerholz, J.-H. Chen et al., “The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs,” Science Translational Medicine, vol. 3, no. 74, Article ID 74ra24, pp. 1–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. D. A. Stoltz, T. Rokhlina, S. E. Ernst et al., “Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs,” The Journal of Clinical Investigation, vol. 123, no. 6, pp. 2685–2693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. C. S. Rogers, D. A. Stoltz, D. K. Meyerholz et al., “Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs,” Science, vol. 321, no. 5897, pp. 1837–1841, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. K. O. McKay, B. R. Wiggs, P. D. Paré, and R. D. Kamm, “Zero-stress state of intra- and extraparenchymal airways from human, pig, rabbit, and sheep lung,” Journal of Applied Physiology, vol. 92, no. 3, pp. 1261–1266, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. J. N. Maina and P. Van Gils, “Morphometric characterization of the airway and vascular systems of the lung of the domestic pig, Sus scrofa: comparison of the airway, arterial and venous systems,” Comparative Biochemistry and Physiology—A Molecular and Integrative Physiology, vol. 130, no. 4, pp. 781–798, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Bradley, F. J. Bourne, and P. Brown, “The respiratory tract immune system in the pig,” Veterinary Pathology, vol. 13, no. 2, pp. 90–97, 1976. View at Google Scholar
  93. D. K. Meyerholz, D. A. Stoltz, E. Namati et al., “Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 10, pp. 1251–1261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. R. J. Adam, A. S. Michalski, C. Bauer et al., “Air trapping and airflow obstruction in newborn cystic fibrosis piglets,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 12, pp. 1434–1441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Rosenfeld, R. L. Gibson, S. McNamara et al., “Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis,” Pediatric Pulmonology, vol. 32, no. 5, pp. 356–366, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. J. L. Burns, R. L. Gibson, S. McNamara et al., “Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis,” Journal of Infectious Diseases, vol. 183, no. 3, pp. 444–452, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Z. Khan, J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. H. Riches, “Early pulmonary inflammation in infants with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 4, pp. 1075–1082, 1995. View at Google Scholar · View at Scopus
  98. J.-H. Chen, D. A. Stoltz, P. H. Karp et al., “Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia,” Cell, vol. 143, no. 6, pp. 911–923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. T. A. Standaert, L. Boitano, J. Emerson et al., “Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials,” Pediatric Pulmonology, vol. 37, no. 5, pp. 385–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. J. C. Davies, M. Davies, D. McShane et al., “Potential difference measurements in the lower airway of children with and without cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 9, pp. 1015–1019, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. D. K. Meyerholz, D. A. Stoltz, A. A. Pezzulo, and M. J. Welsh, “Pathology of gastrointestinal organs in a porcine model of cystic fibrosis,” American Journal of Pathology, vol. 176, no. 3, pp. 1377–1389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. S. M. Blackman, R. Deering-Brose, R. McWilliams et al., “Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis,” Gastroenterology, vol. 131, no. 4, pp. 1030–1039, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. E. C. Benya, A. R. Nussbaum-Blask, and D. M. Selby, “Colonic diverticulitis causing partial bowel obstruction in a child with cystic fibrosis,” Pediatric Radiology, vol. 27, no. 12, pp. 918–919, 1997. View at Publisher · View at Google Scholar · View at Scopus
  104. B. P. O'Sullivan, D. Baker, K. G. Leung, G. Reed, S. S. Baker, and D. Borowitz, “Evolution of pancreatic function during the first year in infants with cystic fibrosis,” Journal of Pediatrics, vol. 162, no. 4, pp. 808–812.e1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Uc, R. Giriyappa, D. K. Meyerholz et al., “Pancreatic and biliary secretion are both altered in cystic fibrosis pigs,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 303, no. 8, pp. G961–G968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. K. N. Lazaridis, M. Strazzabosco, and N. F. Larusso, “The cholangiopathies: disorders of biliary epithelia,” Gastroenterology, vol. 127, no. 5, pp. 1565–1577, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Vítek and M. C. Carey, “Enterohepatic cycling of bilirubin as a cause of ‘black’ pigment gallstones in adult life,” European Journal of Clinical Investigation, vol. 33, no. 9, pp. 799–810, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. D. P. Cook, M. V. Rector, D. C. Bouzek et al., “Cystic fibrosis transmembrane conductance regulator in sarcoplasmic reticulum of airway smooth muscle. Implications for airway contractility,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 4, pp. 417–426, 2016. View at Publisher · View at Google Scholar
  109. M. E. R. Darnell, E. P. Plant, H. Watanabe et al., “Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets,” The Journal of Infectious Diseases, vol. 196, no. 9, pp. 1329–1338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. F. Krammer, R. Hai, M. Yondola et al., “Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets,” Journal of Virology, vol. 88, no. 6, pp. 3432–3442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. J. F. Engelhardt, J. R. Yankaskas, S. A. Ernst et al., “Submucosal glands are the predominant site of CFTR expression in the human bronchus,” Nature Genetics, vol. 2, no. 3, pp. 240–248, 1992. View at Publisher · View at Google Scholar · View at Scopus
  112. R. Dajani, Y. Zhang, P. J. Taft et al., “Lysozyme secretion by submucosal glands protects the airway from bacterial infection,” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 6, pp. 548–552, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. X. Liu, M. Luo, L. Zhang, W. Ding, Z. Yan, and J. F. Engelhardt, “Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia,” American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 3, pp. 313–323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. X. Sun, Z. Yan, Y. Yi et al., “Adeno-associated virus—targeted disruption of the CFTR gene in cloned ferrets,” Journal of Clinical Investigation, vol. 118, no. 4, pp. 1578–1583, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. C. A. Johnson-Delaney, “Ferret nutrition,” Veterinary Clinics of North America: Exotic Animal Practice, vol. 17, no. 3, pp. 449–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  116. D. H. Andersen, “Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study,” American Journal of Diseases of Children, vol. 56, no. 2, pp. 344–399, 1938. View at Publisher · View at Google Scholar
  117. R. W. Shepherd and G. J. Cleghorn, Cystic Fibrosis: Nutritional and Intestinal Disorders, CRC Press, New York, NY, USA, 1989.
  118. W. Lissens, B. Mercier, H. Tournaye et al., “Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities,” Human Reproduction, vol. 11, no. 4, pp. 55–80, 1996. View at Google Scholar · View at Scopus
  119. D. A. Gaillard, F. Carre-Pigeon, and A. Lallemand, “Normal vas deferens in fetuses with cystic fibrosis,” Journal of Urology, vol. 158, no. 4, pp. 1549–1552, 1997. View at Publisher · View at Google Scholar · View at Scopus